Mesoblast joins S&P/ASX 200 Index as global leader in cell therapies.

From GlobeNewswire: 2025-03-06 18:54:28

Mesoblast Limited has been added to the S&P/ASX 200 Index, effective March 6, 2025, on the Australian Stock Exchange, solidifying its position as a global leader in allogeneic cellular medicines for inflammatory diseases. Mesoblast’s proprietary technology platform has led to the development of RYONCIL®, the first FDA-approved mesenchymal stromal cell therapy for pediatric patients with acute graft versus host disease. The company is committed to developing additional cell therapies for various inflammatory conditions, supported by a strong global intellectual property portfolio and advanced manufacturing processes to ensure widespread availability of these life-saving treatments.



Read more at GlobeNewswire: Mesoblast Added to S&P/ASX 200 INDEX